北京志健金瑞生物医药科技

Zhijian Jinrui is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of next-generation small molecule drugs for cancer and autoimmune disorders. The company utilizes an advanced structure-based drug design (SBDD) platform to create highly selective inhibitors for difficult-to-drug targets within the RAS/MAPK signaling pathway. Its lead program, ZJ-101, is a potent SHP2 inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors. Beyond SHP2, the company is advancing a robust pipeline of candidates targeting SOS1 and KRAS mutations to overcome drug resistance in oncology. Zhijian Jinrui is supported by leading venture capital firms including Sequoia China and Matrix Partners China.